The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

NCT03295240 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma
Lymphoma

Interventions

DRUG: BR-I (bendamustine, rituximab, ibrutinib)
DRUG: VEN (Venetoclax)

Sponsor

Memorial Sloan Kettering Cancer Center